These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23797535)

  • 21. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.
    Alquwaizani M; Buckley L; Adams C; Fanikos J
    Curr Emerg Hosp Med Rep; 2013 Jun; 1(2):83-97. PubMed ID: 23687625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics of the anticoagulant activity (APTT) of an algal polysaccharide.
    Cattaneo F; Trento F; Pescador R; Porta R; Ferro L
    Thromb Res; 2002 Mar; 105(5):455-7. PubMed ID: 12062548
    [No Abstract]   [Full Text] [Related]  

  • 23. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 24. Prophylaxis of thromboembolic events in patients with nephrotic syndrome.
    Pincus KJ; Hynicka LM
    Ann Pharmacother; 2013 May; 47(5):725-34. PubMed ID: 23613095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspects of anticoagulation in children.
    Payne JH
    Br J Haematol; 2010 Aug; 150(3):259-77. PubMed ID: 20528873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacology of the new oral anticoagulants].
    Dempfle CE
    Herz; 2012 Jun; 37(4):362-8. PubMed ID: 22565859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic optimisation of the treatment of deep vein thrombosis.
    Iorio A; Agnelli G
    Clin Pharmacokinet; 1997 Feb; 32(2):145-72. PubMed ID: 9068929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Kaye AD; Manchikanti L; Novitch MB; Mungrue IN; Anwar M; Jones MR; Helander EM; Cornett EM; Eng MR; Grider JS; Harned ME; Benyamin RM; Swicegood JR; Simopoulos TT; Abdi S; Urman RD; Deer TR; Bakhit C; Sanapati M; Atluri S; Pasupuleti R; Soin A; Diwan S; Vallejo R; Candido KD; Knezevic NN; Beall D; Albers SL; Latchaw RE; Prabhakar H; Hirsch JA
    Pain Physician; 2019 Jan; 22(1S):S75-S128. PubMed ID: 30717501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PK evaluation of fondaparinux sodium for the treatment of thrombosis.
    Delavenne X; Frappé P; Zufferey P; Mismetti P; Laporte S; Bertoletti L
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):269-77. PubMed ID: 24359588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation.
    Mahieu E; Claes K; Jacquemin M; Evenepoel P; Op De Beek K; Bogaert AM; Kuypers D; Verhamme P; Meijers B
    Artif Organs; 2013 May; 37(5):482-7. PubMed ID: 23461610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
    Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral anticoagulant therapy interruption in children: A single centre experience.
    Campbell S; Monagle P; Newall F
    Thromb Res; 2016 Apr; 140():89-93. PubMed ID: 26928454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor Xa and thrombin as targets for new oral anticoagulants.
    Weitz JI
    Thromb Res; 2011 Jan; 127 Suppl 2():S5-S12. PubMed ID: 21193114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation.
    Fawzy AM; Lip GYH
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):381-398. PubMed ID: 30951640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Old and new antithrombotic drugs in neonates and infants.
    Young G
    Semin Fetal Neonatal Med; 2011 Dec; 16(6):349-54. PubMed ID: 21816695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticoagulation Therapies in Children.
    Young G
    Pediatr Clin North Am; 2017 Dec; 64(6):1257-1269. PubMed ID: 29173784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Avoiding emergency situations under anticoagulant therapy with vitamin K antagonists].
    Dempfle CE; Borggrefe M
    Internist (Berl); 2005 Sep; 46(9):1006-10, 1012-3. PubMed ID: 16082525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.